Endpoint Assessment for Cell Therapy in Patients with Intermittent Claudication and Critical Limb Ischemia
© 2016 Elsevier Inc. All rights reserved. Peripheral artery disease (PAD) affects over eight million Americans and is associated with significant morbidity and mortality as it is a marker of subclinical heart disease and systemic atherosclerosis (Rooke TW et al. J Am Coll Cardiol 2011;58:2020-2045). Patients with PAD are at increased risk for myocardial infarction, stroke, and death (Rooke TW et al. J Am Coll Cardiol 2011;58:2020-2045; European Stroke O et al. Eur Heart J 2011;32: 2851-2906; Jaff MR, Cahill KE, Yu AP, Birnbaum HG, Engelhart LM. Ann Vasc Surg 2010;24:577-587). PAD can be silent, however when symptomatic it is associated with a significant reduction in quality of life and, in its most sobering form, limb amputation (Rooke TW et al. J Am Coll Cardiol 2011;58:2020-2045; European Stroke O et al. Eur Heart J 2011;32: 2851-2906). Given its substantial health burden, PAD has become the focus of many therapeutic developments including drugs, surgical revascularization, endovascular devices, and emerging gene and cellular therapies discussed in this book.
- Regenerative Medicine for Peripheral Artery Disease
Start / End Page
International Standard Book Number 13 (ISBN-13)
Digital Object Identifier (DOI)